The National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded UCI a 5-year, $4.2 million grant to study sporadic inclusion body myositis (sIBM), which affects aging adults ...

Sporadic inclusion body myositis (sIBM) presents with a characteristic clinical phenotype of slow-onset weakness and atrophy, affecting proximal and distal limb muscles and facial and pharyngeal ...

Abcuro, Inc., today announced topline results from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients with ...

DUBLIN--(BUSINESS WIRE)--The "Inclusion Body Myositis (IBM) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Inclusion Body Myositis (IBM) - Pipeline Review, H2 ...

Irvine, CA - April 6, 2021 - The National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded UCI a 5-year, $4.2 million grant to study sporadic inclusion body myositis (sIBM), ...

Peter Frampton, British rock star and icon shared in 2019 that he has inclusion body myositis (IBM), a muscular inflammatory disease that can impact the strength of the legs, arms, and fingers. He has ...

CHARLESTON, S.C. (WCSC) - One man is making it his mission to cross off his bucket list while bringing awareness to a rare medical diagnosis. Chip Galloway was diagnosed with Inclusion Body Myositis, ...

Copenhagen – March 29, 2021 – Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of neurodegenerative rare ...

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK ...

NEWTON, Mass., February 24, 2026--(BUSINESS WIRE)--Abcuro, Inc., today announced topline results from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal ...

Phase 2/3 study did not meet primary or key secondary endpoints; ulviprubart showed a favorable safety and tolerability profile compared to placebo Clinically meaningful slowing of disease progression ...